ResMed Inc (RMD)

Rating: HOLD

HOLD (5-tier) · mature cash generator · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -9% vs spot
• Monte Carlo median implies -18% vs spot
• DCF fair value implies -8% vs spot — but this is terminal-value sensitive (exit-multiple $202 vs Gordon $233, 15% apart), so it carries less weight
• Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -59% vs spot
• Net: reward/risk of 0.1× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At 194.88 (27 June 2026) ResMed trades on roughly 16 times forward earnings, a discount to the med-device peer median near 19 times. That gap says the market is pricing a real probability that GLP-1 weight-loss drugs structurally shrink the sleep-apnoea device pool. The engine treats that fear as a genuine but not base-case outcome: a 20% weight on structural impairment, targeting 88.71, below the 180.27 fifty-two-week low. Our central view sits on ~6% device growth and a 35% operating margin, anchored by the recurring mask and resupply annuity and a DCF that triangulates near 203. The probability-weighted target of 201.62 is only ~3% above spot, so the rating is HOLD, not a call to add. The single most damaging risk is that GLP-1 therapy does more than dent new diagnoses and instead erodes the installed base itself, taking earnings and the multiple down together toward the structural target rather than the mid-cycle one.

The dashboard below is the whole argument on one page: spot ($220) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear is the structural GLP-1 and reimbursement case, at 20%. Its mechanism is not a single soft quarter. Widening GLP-1 use lowers obesity, the dominant driver of obstructive sleep apnoea, so fewer new patients enter the diagnosis funnel each year. The installed base ages out faster than replacements arrive, resupply growth fades, and pricing power weakens as payers tighten. Revenue turns negative, the operating margin compresses toward the high twenties, and the market re-rates ResMed from a quality compounder toward a structurally challenged device maker. Earnings and the multiple fall in tandem, which is why the modelled target of 88.71 sits below the fifty-two-week low.

Key Debate

P/E Multiple explains 78% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.41 vs analyst floor +0.43 → delta -0.03 (n=16 mgmt / 6 Q&A; 0th pctile across the S&P book, z -2.5).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 1000 articles): avg ticker sentiment +0.15 (bullish 24% / bearish 7%)

Scenario Analysis

The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($90) to a 'Bull — Re-Rate' bull case ($353); the probability-weighted blend (PWEV $201) is -9% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $90). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 88.71; probability: 0.2.
• Hospital-Capex / Utilization Recession (17%, $151). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 150.65; probability: 0.17.
• Base — Procedure Volume + Innovation (35%, $209). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 209.24; probability: 0.35.
• Growth — New-Product Cycle / Penetration (20%, $280). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 282.47; probability: 0.2.
• Bull — Re-Rate (8%, $353). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 356.75; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $181 and 29% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (78% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 14x terminal FCF multiple → $202. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 19.03x) implies $226. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 22% of the median — moderate (healthy method disagreement — read the blend with care).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Devices Tools

This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)

Mapping note: name-level 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) + 'Hospital-Capex / Utilization Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — New-Product Cycle / Penetration' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $8B + PV(terminal) $21B = EV $29B; + net cash → equity $29B ÷ diluted shares 0.15B = $202/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $233/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 76% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $226; EV/Rev → $184.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 17x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-06-30 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1.7% of revenue; cash conversion (OCF/NI) 125% — cash-backed.

Catalyst Calendar

• 2026-08-06 (~29d) — Quarterly earnings — est. EPS $2.90 (AV EARNINGS_CALENDAR)
• 2026-09-30 (~84d) — CMS competitive-bidding / DME reimbursement update for PAP devices (authored)
• 2026-11-19 (~134d) — Peer-reviewed GLP-1 + OSA co-therapy readout (real-world resupply cohort) (authored)
• 2027-02-18 (~225d) — Next-gen connected mask / flow-generator platform launch (authored)

Forecast Track Record

• EPS surprise: beat 75.0% of the last 8 quarters; average surprise +2.2%.

Competitive Moat

Wide moat. The AirView cloud install base plus the ~55-65% share of the US flow-generator/mask duopoly (with Philips) support a terminal multiple above the ~16x market level; the falsifiable claim is that if GLP-1 adoption cuts newly-diagnosed OSA device starts by more than ~10% per year on a sustained basis, the annuity resupply moat weakens and the terminal multiple should compress toward the market ~16x rather than the med-device ~19x.

Moat sources:

• AirView / myAir connected-care cloud with recurring mask/consumable resupply annuity
• US mask+flow-generator duopoly with Philips (Philips recall left RMD share gains partly stranded)
• physician/DME distribution relationships and prescription lock-in
• installed-base switching costs once a patient is titrated on a device

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 18.2× forward EPS, vs the house DCF terminal 14.0×, and a peer median 19.03×. The house DCF sits 8% below spot, so the market is pricing in more than the house case — roughly 1.0pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 19.8× (simple median 19.03×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $180–$292, centre $229 (+4% vs spot); spot sits at the 35th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $353.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (50.0); Terminal × ±15% (43.0); Op margin ±3pp (31.0); WACC ±1pp (16.0); Capex intensity ±15% (4.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 14×, FY+5 revenue $7B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Sleep-and-breathing device revenue growth (constant currency, YoY) < 0.02 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Base assumes ~6% device growth. Sub-2% constant-currency growth for two quarters would signal the mid-cycle demand assumption is breaking toward the Hospital-Capex / Utilization Recession path.
• Non-GAAP gross margin < 0.585 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Margin near 59% underpins the 35% operating-margin base. A drop below ~58.5% for two prints would move the earnings mix toward the compressed-margin cyclical and structural cases.
• New-patient diagnosis / device set-up volume (YoY) < 0.0 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). The GLP-1 structural risk operates through fewer new apnoea diagnoses reaching device therapy. A flat-to-negative new-set-up funnel for two prints is the observable early read on structural substitution rather than a demand pause.
• Residual mask / resupply attach revenue growth (YoY) < 0.03 (2 consecutive prints → Mid-Cycle — Procedure & R&D Demand). The recurring resupply annuity is the margin anchor. Growth slipping below ~3% for two prints would show the installed base is not compounding as the base case requires.
• GLP-1 sleep-apnoea label / payer-coverage expansion event >= 1 (single event → Reimbursement / Funding / Utilization Reset). A broad GLP-1 obstructive-sleep-apnoea label with reimbursed coverage is the discrete catalyst that would validate the structural-substitution scenario ahead of the volume data.

Fact / Inference / Speculation

• FACT: Spot $220; 52-week range $180–$292; engine rating HOLD; base-case target $202 (-8%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $201 (-9% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $201 (-9% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.